An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Deach-1 (PD-1) Antibody (BMS-936558) in Subjects with Metastatic Clear Cell Renal Cell Carcinoma (RCC)
Conditions
Renal Cell Carcinoma | Renal Cell Carcinoma (RCC)
Trial Phase
Trial Purpose and Description
Trial Purpose
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Eligibility Criteria
- Sponsor:
- Bristol-Myers Squibb
- Dates:
- July 2011
- Last Updated:
- Study HIC#:
- 1105008541
Clinicaltrials.gov ID: Yale2403179
